Mycophenolate mofetil in myasthenia gravis: The unanswered question

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 14, 2008, Pages 2545-2551

  Phan, C ^a   Sanders, D B ^b   Siddiqi, Z A ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CellCept; Myasthenia gravis; Mycophenolate mofetil; Progressive multifocal leukoencephalopathy

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; PYRIDOSTIGMINE; RAPAMYCIN; STEROID; TACROLIMUS;

ABDOMINAL CRAMP; ANOREXIA; AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRANULOCYTOPENIA; HAND EDEMA; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEG SWELLING; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; MUSCLE CRAMP; MYASTHENIA GRAVIS; NAUSEA; NEPHROTOXICITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; REVIEW; SINGLE DRUG DOSE; VOMITING; WEAKNESS;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 54349114451     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.14.2545     Document Type: Review

References (27)

1. Betana M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review). Neurology 2007;68(1):1-6
2. Levin KH, Richman DP. Myasthenia gravis. Clin Aspects Autoimmune 1989;4:23
3. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow-up study. J Neurol Neurosurg Psychiatry 1989;52(10):1121-7
4. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007;4:1-31
5. Paszcuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15(3):291-8
6. Palace J, Newsom-Davis J, Lecky B. Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50(6):1778-83
7. Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316(12):719-24
8. Ciafaloni E. Mycophenolate mofetil and myasthenia gravis. Lupus 2005;14(Suppl 1):46-9
9. Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 2006;34(3):284-91
10. Allison AC. Mechanism of mycophenolate mofetil. Lupus 2006;14(Suppl):2-8
11. Durez P, Apelboom T, Pira C, et al. Anti-inflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-alpha and upregulation of IL-10 release. Int J Immunopharmacol 1999;21(9):581-7
12. Cohn R, Mirkovich A, Dunlap B, et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999;68(3):411-8
13. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of myocophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46(1):13-58
14. Solomons N, Mamelok R. No pharmacokinetic interaction between mycophenolate mofetil and prednisolone in healthy male volunteers. PU018 The 8th International Congress on SLE; 2007; Shanghai, China
15. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51(3):912-3
16. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur Neurol 2001;46(2):79-82
17. Mowzoon N, Sussman A, Bradley W. Mycophenolate treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001;185(2):119-22
18. Meriggioli MN, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve 2000;23(8):1287-9
19. Lim AKH, Donnan G, Chambers B, Lerino FL. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity: Intern Med J 2007;37(1):55-9
20. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia-gravis: An open-label pilot study. Neurology 2001;56:97-99
21. Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56(1):94-6
22. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61(10):1438-40
23. Meriggioli MN, Rowin J, Richman J, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann NY Acad Sci 2003;998:494-9
24. The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-9
25. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-6
26. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006;142:1447-54
27. Neurath MF, Wanitschke R, Peters M, et al. Randomized trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's Disease. Gut 1999;44:625-8